Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:ACUS OTCMKTS:ALPMY OTCMKTS:ALSE OTCMKTS:AOLS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACUSAcusphere$0.00$0.00▼$0.00N/A-1.850 shsN/AALPMYAstellas Pharma$11.41-0.3%$10.64$8.37▼$12.57$20.65B0.27179,299 shs134,405 shsALSEAlseres Pharmaceuticals$0.01$0.01$0.01▼$0.01N/AN/AN/AN/AAOLSAeolus Pharmaceuticals$0.00$0.00▼$0.01N/A1.3717,010 shsN/AThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACUSAcusphere0.00%0.00%0.00%0.00%+900.00%ALPMYAstellas Pharma0.00%-0.26%+1.42%+19.90%-4.66%ALSEAlseres Pharmaceuticals0.00%0.00%0.00%0.00%0.00%AOLSAeolus Pharmaceuticals0.00%0.00%0.00%0.00%0.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACUSAcusphere$0.00$0.00▼$0.00N/A-1.850 shsN/AALPMYAstellas Pharma$11.41-0.3%$10.64$8.37▼$12.57$20.65B0.27179,299 shs134,405 shsALSEAlseres Pharmaceuticals$0.01$0.01$0.01▼$0.01N/AN/AN/AN/AAOLSAeolus Pharmaceuticals$0.00$0.00▼$0.01N/A1.3717,010 shsN/AThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACUSAcusphere0.00%0.00%0.00%0.00%+900.00%ALPMYAstellas Pharma0.00%-0.26%+1.42%+19.90%-4.66%ALSEAlseres Pharmaceuticals0.00%0.00%0.00%0.00%0.00%AOLSAeolus Pharmaceuticals0.00%0.00%0.00%0.00%0.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACUSAcusphere 0.00N/AN/AN/AALPMYAstellas Pharma 3.00BuyN/AN/AALSEAlseres Pharmaceuticals 0.00N/AN/AN/AAOLSAeolus Pharmaceuticals 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest ALPMY, ACUS, AOLS, and ALSE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/9/2025ALPMYAstellas PharmaZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy9/2/2025ALPMYAstellas PharmaSanford C. BernsteinSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeOutperform ➝ Market Perform(Data available from 9/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACUSAcusphereN/AN/AN/AN/AN/AN/AALPMYAstellas Pharma$12.56B1.64$1.79 per share6.36$5.52 per share2.07ALSEAlseres PharmaceuticalsN/AN/AN/AN/AN/AN/AAOLSAeolus PharmaceuticalsN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACUSAcusphereN/AN/A0.00N/AN/AN/AN/AN/AN/AALPMYAstellas Pharma$334.93M$0.3038.0316.78N/A4.34%19.67%8.71%10/29/2025 (Estimated)ALSEAlseres PharmaceuticalsN/AN/A0.00∞N/AN/AN/AN/AN/AAOLSAeolus PharmaceuticalsN/AN/A0.00N/AN/AN/AN/AN/AN/ALatest ALPMY, ACUS, AOLS, and ALSE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails7/30/2025Q1 2026ALPMYAstellas Pharma$0.1356$0.40+$0.2644$0.26$3.20 billion$3.41 billionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACUSAcusphereN/AN/AN/AN/AN/AALPMYAstellas Pharma$0.342.98%N/A113.33%N/AALSEAlseres PharmaceuticalsN/AN/AN/AN/AN/AAOLSAeolus PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACUSAcusphereN/AN/AN/AALPMYAstellas Pharma0.381.170.89ALSEAlseres PharmaceuticalsN/AN/AN/AAOLSAeolus PharmaceuticalsN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACUSAcusphereN/AALPMYAstellas PharmaN/AALSEAlseres PharmaceuticalsN/AAOLSAeolus PharmaceuticalsN/AInsider OwnershipCompanyInsider OwnershipACUSAcusphere4.60%ALPMYAstellas PharmaN/AALSEAlseres Pharmaceuticals8.94%AOLSAeolus Pharmaceuticals66.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACUSAcusphere118N/AN/ANot OptionableALPMYAstellas Pharma14,7541.81 billionN/ANot OptionableALSEAlseres Pharmaceuticals3N/AN/ANot OptionableAOLSAeolus Pharmaceuticals4N/AN/ANot OptionableALPMY, ACUS, AOLS, and ALSE HeadlinesRecent News About These CompaniesAOLS Aeolus Pharmaceuticals, Inc.August 28, 2024 | seekingalpha.comAeolus Awarded Contract Fully Valued at $118 Million from BARDA to Develop Treatment for Lung Acute Radiation SyndromeAugust 19, 2024 | br.advfn.comAeolus Pharmaceuticals Announces Appointment of Russell L. Skibsted as Senior Vice President and Chief Financial OfficerAugust 19, 2024 | br.advfn.comSDCI.P:CA St. Davids Capital Inc.July 20, 2024 | seekingalpha.comASLN ASLAN Pharmaceuticals LimitedApril 27, 2024 | seekingalpha.comAeolus Tyre Co Ltd (600469)January 12, 2024 | investing.comAeolus: Wind-mapping space laser is losing powerDecember 16, 2023 | bbc.comBOusted Head of Virus Vaccine Effort Accuses White House of RetaliationOctober 7, 2023 | courthousenews.comCAeolus Announces Third Quarter Fiscal Year 2015 Financial ResultsFebruary 21, 2023 | yahoo.comVoxtur rolls out attorney opinion letters for VA loansOctober 29, 2022 | housingwire.comHAeolus Pharmaceuticals IncOctober 8, 2022 | reuters.comAeolus Pharmaceuticals, Inc. (AOLS)September 13, 2022 | uk.finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeALPMY, ACUS, AOLS, and ALSE Company DescriptionsAcusphere OTCMKTS:ACUSAcusphere, Inc. operates as a specialty pharmaceutical company that develops and commercializes cardiovascular drugs. It offers Imagify (perflubutane polymer microspheres), a cardiovascular drug that evaluates myocardial perfusion and detects coronary artery disease. It provides Imagify as an injectable suspension. The company was formerly known as Polymers For Medicine, Inc. and changed its name to Acusphere, Inc. in March 2004. Acusphere, Inc. was founded in 1993 and is based in Watertown, Massachusetts.Astellas Pharma OTCMKTS:ALPMY$11.41 -0.04 (-0.35%) As of 03:58 PM EasternAstellas Pharma Inc. manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer. It also offers Evrenzo, a treatment for anemia associated with chronic kidney disease; Betanis/Myrabetriq/BETMIGA, a treatment for overactive bladder; and Prograf and Advagraf/Graceptor/ASTAGRAF XL immunosuppressants. Th company has a research collaboration with Vivtex Corporation to evaluate Vivtex's GI-ORIS screening and formulation platform technology to support the development of novel and oral versions of a therapeutic candidate provided by Astellas; and a partnership agreement with Roche Diabetes Care Japan Co., Ltd. to develop and commercialize integrated diabetes self-management solution. The company was founded in 1923 and is headquartered in Tokyo, Japan.Alseres Pharmaceuticals OTCMKTS:ALSE$0.0050 0.00 (0.00%) As of 10/18/2024Alseres Pharmaceuticals, Inc. focuses on developing diagnostic and therapeutic products primarily for disorders in the central nervous system. Its lead product candidate is Altropane, a molecular imaging agent for the diagnosis of Parkinson's disease and dementia. The company was formerly known as Boston Life Sciences, Inc. and changed its name to Alseres Pharmaceuticals, Inc. in June 2007. Alseres Pharmaceuticals, Inc. was founded in 1972 and is based in Auburndale, Massachusetts.Aeolus Pharmaceuticals OTCMKTS:AOLSAeolus Pharmaceuticals, Inc., a biopharmaceutical company, develops a platform of novel compounds for use in biodefense, fibrosis, oncology, infectious, and central nervous system diseases in the United States. The company develops a class of catalytic antioxidant compounds as medical countermeasures against nuclear, radiological, and chemical weapons, as well as for diseases and disorders of the respiratory system, central nervous system, and oncology. Its lead compound includes AEOL 10150 that has completed two Phase I clinical trials, which is developed against the pulmonary sub-syndrome of acute radiation syndrome; and for use as a medical countermeasure for exposure to chemical vesicants and nerve agents. The company is also developing AEOL 11114B, AEOL 11203, and AEOL 11207 for the treatment of Parkinson's disease, as well as AEOL 20415 for treating infectious diseases. Aeolus Pharmaceuticals, Inc. was founded in 1994 and is based in Mission Viejo, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir’s Commercial Growth Story Is Just Getting Started The Applied Digital Breakout Is Only the Beginning $100 Million Buyback in Upwork Stock Follows a Strong Quarter Royal Caribbean's 33% Dividend Hike Signals Deeper Growth MarketBeat Week in Review – 09/08 - 09/12 Adobe’s Rebound Has Room to Run: 25% Upside by Year-End Wall Street Eyes +30% Upside in Synopsys After Huge Earnings Fall Meta's $600B U.S. Investment: Bearish or Bullish for Shares? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
